{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:30:00Z","timestamp":1792873800296,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T00:00:00Z","timestamp":1559606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T00:00:00Z","timestamp":1559606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Australian National Health and Medical Research Council","award":["1128147"],"award-info":[{"award-number":["1128147"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13063-019-3450-0","type":"journal-article","created":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T13:02:47Z","timestamp":1559653367000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["A study protocol for the N-ICE trial: A randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine (\u201cice\u201d) dependence"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2833-4830","authenticated-orcid":false,"given":"Rebecca","family":"McKetin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia M.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyna","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan I.","family":"Lubman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dietze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Higgs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda L.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"te Pas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamsin","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramez","family":"Bathish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayle","family":"Raftery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Arunogiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Cordaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Berk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,4]]},"reference":[{"key":"3450_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.18356\/c595e10f-en","volume-title":"World Drug Report 2017","author":"United Nations Office on Drugs and Crime","year":"2017","unstructured":"United Nations Office on Drugs and Crime. World Drug Report 2017. New York: United Nations; 2017. p. 13\u201320."},{"key":"3450_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.drugalcdep.2013.12.025","volume":"137","author":"L Degenhardt","year":"2014","unstructured":"Degenhardt L, Baxter AJ, Lee YY, Hall W, Sara GE, Johns N, Flaxman A, Whiteford HA, Vos T. The global epidemiology and burden of psychostimulant dependence: findings from the Global Burden of Disease Study 2010. Drug Alcohol Depend. 2014;137:36\u201347.","journal-title":"Drug Alcohol Depend"},{"key":"3450_CR3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/S0140-6736(10)60753-2","volume":"376","author":"G Colfax","year":"2010","unstructured":"Colfax G, Santos G-M, Chu P, Vittinghoff E, Pluddemann A, Kumar S, Hart C. Amphetamine-group substances and HIV. Lancet. 2010;376:458\u201374.","journal-title":"Lancet"},{"key":"3450_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s13643-016-0370-x","volume":"5","author":"M Bhatt","year":"2016","unstructured":"Bhatt M, Zielinski L, Baker-Beal L, Bhatnagar N, Mouravska N, Laplante P, Worster A, Thabane L, Samaan Z. Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis. Syst Rev. 2016;5:189.","journal-title":"Syst Rev"},{"key":"#cr-split#-3450_CR5.1","doi-asserted-by":"crossref","unstructured":"Shoptaw SJ, Kao U, Ling W. Treatment for amphetamine psychosis. [update of Cochrane Database Syst Rev. 2008;(4):CD003026","DOI":"10.1002\/14651858.CD003026.pub2"},{"key":"#cr-split#-3450_CR5.2","unstructured":"PMID: 18843639]. Cochrane Database Syst Rev. 2009. https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD003026.pub3\/full ."},{"key":"3450_CR6","doi-asserted-by":"crossref","unstructured":"Shoptaw SJ, Kao U, Heinzerling K, Ling W. Treatment for amphetamine withdrawal. Cochrane Database Syst Rev. 2009. https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD003021.pub2\/full .","DOI":"10.1002\/14651858.CD003021.pub2"},{"key":"3450_CR7","doi-asserted-by":"publisher","first-page":"e1002715","DOI":"10.1371\/journal.pmed.1002715","volume":"15","author":"F De Crescenzo","year":"2018","unstructured":"De Crescenzo F, Ciabattini M, Loreto G, De Giorgi R, Del Giovane C, Cassar C, Janiri L, Clark N, Ostacher MJ, Cipriani A. Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: a systematic review and meta-analysis. PLoS Med. 2018;15:e1002715.","journal-title":"PLoS Med"},{"key":"3450_CR8","doi-asserted-by":"crossref","unstructured":"Smith LA, Gates S, Foxcroft D. Therapeutic communities for substance related disorder. Cochrane Database Syst Rev. 2006. https:\/\/doi.org\/\/10.1002\/14651858.CD005338.pub2 .","DOI":"10.1002\/14651858.CD005338.pub2"},{"key":"3450_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0740-5472(03)00067-9","volume":"25","author":"MC Roebuck","year":"2003","unstructured":"Roebuck MC, French MT, McLellan AT. DATStats: results from 85 studies using the Drug Abuse Treatment Cost Analysis Program. J Subst Abus Treat. 2003;25:51\u20137.","journal-title":"J Subst Abus Treat"},{"key":"3450_CR10","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3109\/10826084.2014.891615","volume":"49","author":"E Pullen","year":"2014","unstructured":"Pullen E, Oser C. Barriers to substance abuse treatment in rural and urban communities: counselor perspectives. Subst Use Misuse. 2014;49:891\u2013901.","journal-title":"Subst Use Misuse"},{"key":"3450_CR11","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/wps.20457","volume":"16","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, Glantz M, Evans-Lacko S, Sadikova E, Sampson N, Thornicroft G, Aguilar-Gaxiola S, Al-Hamzawi A, Alonso J, Helena Andrade L, Bruffaerts R, Bunting B, Bromet EJ, Miguel Caldas de Almeida J, de Girolamo G, Florescu S, Gureje O, Maria Haro J, Huang Y, Karam A, Karam EG, Kiejna A, Lee S, Lepine J-P, Levinson D, Elena Medina-Mora M, Nakamura Y, Navarro-Mateu F, Pennell B-E, Posada-Villa J, Scott K, Stein DJ, Ten Have M, Torres Y, Zarkov Z, Chatterji S, Kessler RC, World Health Organization\u2019s World Mental Health Surveys c. Estimating treatment coverage for people with substance use disorders: an analysis of data from the World Mental Health Surveys. World Psychiatry. 2017;16:299\u2013307.","journal-title":"World Psychiatry"},{"key":"3450_CR12","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jamapsychiatry.2013.2207","volume":"70","author":"RM Brown","year":"2013","unstructured":"Brown RM, Kupchik YM, Kalivas PW. The story of glutamate in drug addiction and of N-acetylcysteine as a potential pharmacotherapy. JAMA Psychiat. 2013;70:895\u20137.","journal-title":"JAMA Psychiat"},{"key":"3450_CR13","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/ajad.12620","volume":"26","author":"MS Duailibi","year":"2017","unstructured":"Duailibi MS, Cordeiro Q, Brietzke E, Ribeiro M, LaRowe S, Berk M, Trevizol AP. N-acetylcysteine in the treatment of craving in substance use disorders: Systematic review and meta-analysis. Am J Addict. 2017;26:660\u20136.","journal-title":"Am J Addict"},{"key":"3450_CR14","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1521-0391.2013.12034.x","volume":"22","author":"SD LaRowe","year":"2013","unstructured":"LaRowe SD, Kalivas PW, Nicholas JS, Randall PK, Mardikian PN, Malcolm RJ. A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence. Am J Addict. 2013;22:443\u201352.","journal-title":"Am J Addict"},{"key":"3450_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1521-0391.2009.00027.x","volume":"19","author":"KM Gray","year":"2010","unstructured":"Gray KM, Watson NL, Carpenter MJ, Larowe SD. N-acetylcysteine (NAC) in young marijuana users: an open-label pilot study. Am J Addict. 2010;19:187\u20139.","journal-title":"Am J Addict"},{"key":"3450_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.pnpbp.2006.10.001","volume":"31","author":"PN Mardikian","year":"2007","unstructured":"Mardikian PN, LaRowe SD, Hedden S, Kalivas PW, Malcolm RJ. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: A pilot study. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007;31:389\u201394.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"3450_CR17","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1176\/ajp.2007.164.7.1115","volume":"164","author":"SD LaRowe","year":"2007","unstructured":"LaRowe SD, Myrick H, Hedden S, Mardikian P, Saladin M, McRae A, Brady K, Kalivas PW, Malcolm R. Is cocaine desire reduced by N-acetylcysteine? Am J Psychiatr. 2007;164:1115\u20137.","journal-title":"Am J Psychiatr"},{"key":"3450_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1179\/1351000215Y.0000000004","volume":"20","author":"E Prado","year":"2015","unstructured":"Prado E, Maes M, Piccoli LG, Baracat M, Barbosa DS, Franco O, Dodd S, Berk M, Vargas Nunes SO. N-acetylcysteine for therapy-resistant tobacco use disorder: a pilot study. Redox Rep. 2015;20:215\u201322.","journal-title":"Redox Rep"},{"key":"3450_CR19","first-page":"28","volume":"18","author":"SG Mousavi","year":"2015","unstructured":"Mousavi SG, Sharbafchi MR, Salehi M, Peykanpour M, Karimian Sichani N, Maracy M. The Efficacy of N-Acetylcysteine in the Treatment of Methamphetamine Dependence: A Double-blind Controlled, Crossover Study. Arch Iran Med. 2015;18:28\u201333.","journal-title":"Arch Iran Med"},{"key":"3450_CR20","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1038\/sj.npp.1300512","volume":"29","author":"K Hashimoto","year":"2004","unstructured":"Hashimoto K, Tsukada H, Nishiyama S, Fukumoto D, Kakiuchi T, Shimizu E, Iyo M. Protective effects of N-acetyl-L-cysteine on the reduction of dopamine transporters in the striatum of monkeys treated with methamphetamine. Neuropsychopharmacology. 2004;29:2018\u201323.","journal-title":"Neuropsychopharmacology"},{"key":"3450_CR21","doi-asserted-by":"publisher","first-page":"9414","DOI":"10.1523\/JNEUROSCI.21-23-09414.2001","volume":"21","author":"ND Volkow","year":"2001","unstructured":"Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M, Gatley SJ, Miller E, Hitzemann R, Ding YS, Logan J. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci. 2001;21:9414\u20138.","journal-title":"J Neurosci"},{"issue":"Suppl 1","key":"3450_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1360-0443.2006.01782.x","volume":"102","author":"L Chang","year":"2007","unstructured":"Chang L, Alicata D, Ernst T, Volkow N. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction. 2007;102(Suppl 1):16\u201332.","journal-title":"Addiction"},{"key":"3450_CR23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1001\/archpsyc.63.1.90","volume":"63","author":"Y Sekine","year":"2006","unstructured":"Sekine Y, Ouchi Y, Takei N, Yoshikawa E, Nakamura K, Futatsubashi M, Okada H, Minabe Y, Suzuki K, Iwata Y, Tsuchiya KJ, Tsukada H, Iyo M, Mori N. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch Gen Psychiatry. 2006;63:90\u2013100.","journal-title":"Arch Gen Psychiatry"},{"key":"3450_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1001\/archpsyc.61.1.73","volume":"61","author":"ED London","year":"2004","unstructured":"London ED, Simon SL, Berman SM, Mandelkern MA, Lichtman AM, Bramen J, Shinn AK, Miotto K, Learn J, Dong Y, Matochik JA, Kurian V, Newton T, Woods R, Rawson R, Ling W. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry. 2004;61:73\u201384.","journal-title":"Arch Gen Psychiatry"},{"key":"3450_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1503\/jpn.100057","volume":"36","author":"O Dean","year":"2011","unstructured":"Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci. 2011;36:78.","journal-title":"J Psychiatry Neurosci"},{"key":"3450_CR26","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/10826084.2018.1521430","volume":"54","author":"A Voce","year":"2019","unstructured":"Voce A, McKetin R, Calabria B, Burns R, Castle DJ. A systematic review of the symptom profile and course of methamphetamine associated psychosis. Subst Use Misuse. 2019;54:549.","journal-title":"Subst Use Misuse"},{"key":"3450_CR27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.drugalcdep.2016.01.018","volume":"161","author":"R McKetin","year":"2016","unstructured":"McKetin R, Dawe S, Burns RA, Hides L, Kavanagh DJ, Teesson M, Mc DYR, Voce A, Saunders JB. The profile of psychiatric symptoms exacerbated by methamphetamine use. Drug Alcohol Depend. 2016;161:104\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"3450_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0149-2918(00)88479-9","volume":"22","author":"EM Grandjean","year":"2000","unstructured":"Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther. 2000;22:209\u201321.","journal-title":"Clin Ther"},{"key":"3450_CR29","unstructured":"Anonymous. Cetylev (TM) (acetylcysteine) effervescent tablets for oral solution [Full prescribing information]. United States (U.S.). Washington, DC: Food and Drug Administration; 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/207916s003lbl.pdf ."},{"key":"3450_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/dar.12414","volume":"36","author":"R McKetin","year":"2017","unstructured":"McKetin R, Dean OM, Baker AL, Carter G, Turner A, Kelly PJ, Berk M. A potential role for N-acetylcysteine in the management of methamphetamine dependence. Drug Alcohol Rev. 2017;36:153\u20139.","journal-title":"Drug Alcohol Rev"},{"key":"3450_CR31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1037\/0022-006X.68.1.134","volume":"68","author":"W Fals-Stewart","year":"2000","unstructured":"Fals-Stewart W, O'Farrell TJ, Freitas TT, McFarlin SK, Rutigliano P. The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties. J Consult Clin Psychol. 2000;68:134\u201344.","journal-title":"J Consult Clin Psychol"},{"key":"3450_CR32","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/add.12472","volume":"109","author":"J May","year":"2014","unstructured":"May J, Andrade J, Kavanagh DJ, Feeney GFX, Gullo MJ, Statham DJ, Skorka-Brown J, Connolly JM, Cassimatis M, Young RM, Connor JP. The Craving Experience Questionnaire: a brief, theory-based measure of consummatory desire and craving. Addiction. 2014;109:728\u201335.","journal-title":"Addiction"},{"key":"3450_CR33","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1046\/j.1360-0443.1995.9056072.x","volume":"90","author":"M Gossop","year":"1995","unstructured":"Gossop M, Darke S, Griffiths P, Hando J, Powis B, Hall W, Strang J. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction. 1995;90:607\u201314.","journal-title":"Addiction"},{"key":"3450_CR34","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/j.1360-0443.1997.tb02953.x","volume":"92","author":"L Topp","year":"1997","unstructured":"Topp L, Mattick RP. Choosing a cut-off on the Severity of Dependence Scale (SDS) for amphetamine users. Addiction. 1997;92:839\u201345.","journal-title":"Addiction"},{"key":"3450_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1046\/j.1440-1614.1999.00517.x","volume":"33","author":"M Srisurapanont","year":"1999","unstructured":"Srisurapanont M, Jarusuraisin N, Jittiwutikan J. Amphetamine withdrawal: I. Reliability, validity and factor structure of a measure. Aust N Z J Psychiatry. 1999;33:89\u201393.","journal-title":"Aust N Z J Psychiatry"},{"key":"3450_CR36","first-page":"594","volume":"12","author":"D Lukoff","year":"1986","unstructured":"Lukoff D, Nuechterlein KH, Ventura J. Manual for the expanded Brief Psychiatric Rating Scale. Schizophr Bull. 1986;12:594\u2013602.","journal-title":"Schizophr Bull"},{"key":"3450_CR37","first-page":"221","volume":"3","author":"J Ventura","year":"1993","unstructured":"Ventura J, Green MF, Shaner A, Liberman RP. Training and quality assurance with the Brief Psychiatric Rating Scale: \u2018the drift busters\u2019. Int J Methods Psychiatr Res. 1993;3:221\u201344.","journal-title":"Int J Methods Psychiatr Res"},{"key":"3450_CR38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.","journal-title":"Health Qual Life Outcomes"},{"key":"3450_CR39","unstructured":"NCCIH Clinical Research Toolbox. 2018. https:\/\/nccih.nih.gov\/grants\/toolbox . Accessed 27 May 2019."},{"key":"3450_CR40","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727\u201336.","journal-title":"Qual Life Res"},{"key":"3450_CR41","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1360-0443.1992.tb02719.x","volume":"87","author":"S Darke","year":"1992","unstructured":"Darke S, Hall W, Wodak A, Heather N, Ward J. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Br J Addict. 1992;87:733\u201342.","journal-title":"Br J Addict"},{"key":"3450_CR42","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1111\/j.1360-0443.2012.03933.x","volume":"107","author":"R McKetin","year":"2012","unstructured":"McKetin R, Najman J, Baker A, Lubman D, Dawe S, Ali R, Lee N, Mattick R, Mamun A. Evaluating the impact of community-based treatment options on methamphetamine use: findings from the Methamphetamine Treatment Evaluation Study (MATES). Addiction. 2012;107:1998\u20132008.","journal-title":"Addiction"},{"key":"3450_CR43","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s001270050026","volume":"33","author":"G Andrews","year":"1998","unstructured":"Andrews G, Peters L. The psychometric properties of the Composite International Diagnostic Interview. Soc Psychiatry Psychiatr Epidemiol. 1998;33:80\u20138.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"Suppl 20","key":"3450_CR44","first-page":"22","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22\u201333 quiz 4\u201357.","journal-title":"J Clin Psychiatry"},{"key":"3450_CR45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1017\/S0033291705005969","volume":"36","author":"DJ Castle","year":"2006","unstructured":"Castle DJ, Jablensky A, McGrath JJ, Carr V, Morgan V, Waterreus A, Valuri G, Stain H, McGuffin P, Farmer A. The diagnostic interview for psychoses (DIP): development, reliability and applications. Psychol Med. 2006;36:69\u201380.","journal-title":"Psychol Med"},{"key":"3450_CR46","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1111\/j.1360-0443.1993.tb02042.x","volume":"88","author":"N Heather","year":"1993","unstructured":"Heather N, Rollnick S, Bell A. Predictive validity of the Readiness to Change Questionnaire. Addiction. 1993;88:1667\u201377.","journal-title":"Addiction"},{"key":"3450_CR47","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0920-9964(03)00189-0","volume":"68","author":"AT Beck","year":"2004","unstructured":"Beck AT, Baruch E, Balter JM, Steer RA, Warman DM. A new instrument for measuring insight: the Beck Cognitive Insight Scale. Schizophr Res. 2004;68:319\u201329.","journal-title":"Schizophr Res"},{"key":"3450_CR48","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1600-0447.1994.tb01487.x","volume":"89","author":"M Birchwood","year":"1994","unstructured":"Birchwood M, Smith J, Drury V, Healy J, Macmillan F, Slade M. A self-report Insight Scale for psychosis: reliability, validity and sensitivity to change. Acta Psychiatr Scand. 1994;89:62\u20137.","journal-title":"Acta Psychiatr Scand"},{"key":"3450_CR49","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1192\/bjp.183.3.228","volume":"183","author":"P Moran","year":"2003","unstructured":"Moran P, Leese M, Lee T, Walters P, Thornicroft G, Mann A. Standardised Assessment of Personality - Abbreviated Scale (SAPAS): preliminary validation of a brief screen for personality disorder. Br J Psychiatry. 2003;183:228\u201332.","journal-title":"Br J Psychiatry"},{"key":"3450_CR50","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jsat.2013.02.003","volume":"45","author":"B Quinn","year":"2013","unstructured":"Quinn B, Stoov\u00e9 M, Dietze P. Factors associated with professional support access among a prospective cohort of methamphetamine users. J Subst Abus Treat. 2013;45:235\u201341.","journal-title":"J Subst Abus Treat"},{"key":"3450_CR51","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/j.1465-3362.2012.00471.x","volume":"32","author":"R McKetin","year":"2013","unstructured":"McKetin R, Dunlop AJ, Holland RM, Sutherland RA, Baker AL, Salmon AM, Hudson SL. Treatment outcomes for methamphetamine users receiving outpatient counselling from the Stimulant Treatment Program in Australia. Drug Alcohol Rev. 2013;32:80\u20137.","journal-title":"Drug Alcohol Rev"},{"key":"3450_CR52","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1001\/archinternmed.2011.1307","volume":"172","author":"GO Ogedegbe","year":"2012","unstructured":"Ogedegbe GO, Boutin-Foster C, Wells MT, et al. A randomized controlled trial of positive-affect intervention and medication adherence in hypertensive african americans. Arch Intern Med. 2012;172:322\u20136.","journal-title":"Arch Intern Med"},{"key":"3450_CR53","volume-title":"Research into methamphetamine use in the Australian Capital Territory. Perth","author":"R McKetin","year":"2017","unstructured":"McKetin R, Voce A, Burns R. Research into methamphetamine use in the Australian Capital Territory. Perth. Australia: National Drug Research Institute; 2017."},{"key":"3450_CR54","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/09595230410001704190","volume":"23","author":"J Shearer","year":"2004","unstructured":"Shearer J, Gowing LR. Pharmacotherapies for problematic psychostimulant use: a review of current research. Drug Alcohol Rev. 2004;23:203\u201311.","journal-title":"Drug Alcohol Rev"},{"key":"3450_CR55","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1111\/j.1360-0443.2006.01496.x","volume":"101","author":"R McKetin","year":"2006","unstructured":"McKetin R, McLaren J, Lubman DI, Hides L. The prevalence of psychotic symptoms among methamphetamine users. Addiction. 2006;101:1473\u20138.","journal-title":"Addiction"},{"key":"3450_CR56","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/nyas.12501","volume":"1327","author":"KM Carroll","year":"2014","unstructured":"Carroll KM. Lost in translation? Moving contingency management and cognitive behavioral therapy into clinical practice. Ann N Y Acad Sci. 2014;1327:94\u2013111.","journal-title":"Ann N Y Acad Sci"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3450-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-019-3450-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3450-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T03:47:06Z","timestamp":1721360826000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-3450-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,4]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3450"],"URL":"https:\/\/doi.org\/10.1186\/s13063-019-3450-0","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,4]]},"assertion":[{"value":"9 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This trial has been approved by all relevant human research ethics committees: Eastern Health (E21\u20132017), Barwon Health (17\/202), the University of Wollongong and the Illawarra Shoalhaven Local Health District Health (2017\/549) and Curtin University (HRE2018\u20130205). All participants provide informed consent prior to participation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"OMD has received grant support from Lilly and ASBDD\/Servier and in-kind support from BioMedica Nutracuticals, NutritionCare and Bioceuticals. MB has received grant support from Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Organon, the Meat and Livestock Board, Novartis, Mayne Pharma and Servier; has been a speaker for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay and Wyeth; and has served as a consultant to AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck and Servier. DIL has provided consultancy advice to Lundbeck and Indivior, and has received travel support and speaker honoraria from Astra Zeneca, Indivior, Janssen, Lundbeck, Servier and Shire. PD has received investigator-initiated funding from Gilead Sciences, an untied educational grant from Indivior and is an unpaid member of an advisory board for Mundipharma for work unrelated to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"325"}}